Durataz

# Durataz ## Overview - **Classification**: Extended-spectrum penicillin/beta-lactamase inhibitor combination. - **Mechanism**: Piperacillin inhibits bacterial cell wall synthesis. Tazobactam protects piperacillin by irreversibly binding to many bacterial beta-lactamase enzymes. ## Primary Indications 1. **Nosocomial Pneumonia**: Including ventilator-associated pneumonia (VAP). 2. **Complicated Intra-abdominal Infections**: Such as appendicitis, peritonitis. 3. **Complicated Skin and Skin Structure Infections**: Including cellulitis, abscesses. 4. **Diabetic Foot Infections**: With osteomyelitis not requiring debridement. 5. **Complicated Urinary Tract Infections**: Including pyelonephritis. ## Adult Dosing ### Standard Dosing **Nosocomial Pneumonia (including VAP)** - **Dose**: **4.5 g (4g piperacillin/0.5g tazobactam)** - **Frequency**: Every **6 hours** - **Route**: IV infusion over **30 minutes** (extended infusion over 3-4 hours often preferred for critically ill). - **Duration**: 7-14 days based on clinical response. **Complicated Intra-abdominal, Complicated Skin/Skin Structure, Diabetic Foot, Complicated UTI** - **Dose**: **3.375 g (3g piperacillin/0.375g tazobactam)** - **Frequency**: Every **6 hours** - **Route**: IV infusion over **30 minutes**. - **Duration**: 5-14 days based on clinical response. ### Dose Adjustments - **Renal Impairment**: - **CrCl >40 mL/min**: No adjustment. - **CrCl 20-40 mL/min**: **3.375 g** every **8 hours**. - **CrCl <20 mL/min**: **2.25 g** every **8 hours**. - **Hemodialysis**: **2.25 g** every **12 hours**, with an additional **0.75 g** after each dialysis session. - **Hepatic Impairment**: No specific dose adjustment recommended. Monitor LFTs. - **Elderly Patients**: Adjust based on renal function; monitor closely. ## Pediatric Dosing ### Neonates (0-28 days) - **Use in neonates is not well-established** and generally **not recommended** due to limited safety/efficacy data. - **If used (off-label, extreme caution)**: - **Dose**: **50 mg/kg** (piperacillin component) per dose. - **Frequency**: Every **8-12 hours** (adjusted based on gestational/postnatal age, renal function). - **Maximum**: Max **80 mg/kg/day** piperacillin component in this age group. - **Special Notes**: Monitor renal function closely due to immature clearance. ### Infants (1-12 months) - **Indication**: Complicated appendicitis, other serious infections (often off-label). - **Dose**: **80 mg/kg** (piperacillin component) per dose. - **Frequency**: Every **8 hours**. - **Maximum**: **4.5 g (piperacillin/tazobactam)** per dose. ### Children (1-12 years) - **Indication**: Complicated appendicitis, serious infections. - **Dose**: **80 mg/kg** (piperacillin component) per dose. - **Frequency**: Every **6-8 hours**. - **Maximum**: **4.5 g (piperacillin/tazobactam)** per dose (adult dose equivalent). - **Note**: For cystic fibrosis, doses up to **100 mg/kg** piperacillin component every **6 hours** may be used (max **6 g** per dose). ### Adolescents (13-18 years) - **Dose**: Typically follows **adult dosing** guidelines. - **Maximum**: **4.5 g** every **6 hours** (for pneumonia) or **3.375 g** every **6 hours** (for other indications). - **Consider weight**: Use pediatric mg/kg dosing if patient is significantly underweight. ## Safety Information ### Contraindications - **Absolute**: History of **severe allergic reaction** (e.g., anaphylaxis, SJS) to penicillins, cephalosporins, or other beta-lactams. - **Absolute**: History of **tazobactam allergy** or other beta-lactamase inhibitors. ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea, Nausea. - **Common (1-10%)**: Rash, Vomiting, Headache, Insomnia, Constipation, Elevated LFTs (AST/ALT). - **Serious but Rare**: Anaphylaxis, Seizures, Pseudomembranous colitis (C. difficile), Interstitial nephritis, Neutropenia, Thrombocytopenia, Hemolytic anemia. ### Key Drug Interactions - **Warfarin**: May **prolong PT/INR**. Monitor **INR** closely, adjust warfarin dose as needed. - **Methotrexate**: Decreased renal clearance of methotrexate. Monitor **methotrexate levels**, consider alternative. - **Probenecid**: **Increases piperacillin/tazobactam levels** and prolongs half-life. Not generally recommended. - **Aminoglycosides**: Physical incompatibility when mixed; administer **separately**. Increased risk of **nephrotoxicity**. - **Vecuronium**: May **prolong neuromuscular blockade**. Monitor for prolonged paralysis. ## Monitoring & Follow-up - **Before Treatment**: Obtain complete **allergy history**, baseline **renal and hepatic function (SCr, BUN, LFTs)**. - **During Treatment**: - **Renal function**: Monitor **SCr, BUN** regularly (e.g., every 2-3 days), especially in renal impairment. - **Hepatic function**: Monitor **LFTs** (AST/ALT) periodically with prolonged therapy. - **Hematologic**: Monitor **CBC** (WBC, platelets) weekly if therapy >7 days. - **Fluid & Electrolytes**: Monitor for **hypokalemia** with prolonged use. - **Clinical Signs**: Observe for new **rashes/allergic reactions**, signs of **superinfection (C. difficile)**, or **neurological changes (seizures)**. ## Clinical Pearls - 💡 **Infusion Rate**: Standard infusion is **30 minutes**. Extended infusions (3-4 hours) are often used to optimize efficacy in critically ill or for resistant organisms. - 💡 **Compatibility**: **Incompatible** with lactated Ringer's and aminoglycosides. Administer in separate lines/times. - 💡 **C. difficile Risk**: High risk of **Clostridioides difficile-associated diarrhea (CDAD)**. Counsel patients on symptoms like severe diarrhea. - 💡 **Seizure Risk**: Dose accumulation in renal dysfunction can increase **seizure risk**. Ensure appropriate dose adjustments. - 💡 **Drug-induced Fever**: Can cause drug-induced fever. Exclude other causes before discontinuing. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.